The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferative neoplasms or myelodysplasia syndrome. The present invention also relates to screening assays allowing the identification of such compounds.

The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferative neoplasms or myelodysplasia syndrome. The present invention also relates to screening assays allowing the identification of such compounds.

The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby.

Systems and methods for the treatment of plants, including decarboxylation, photo-oxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

Systems and methods for the treatment of plants, including decarboxylation, photo-oxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

Systems and methods for the treatment of plants, including decarboxylation, photooxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

Systems and methods for the treatment of plants, including decarboxylation, photooxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

An optical article including one or more photochromic compounds selected from group consisting of compound represented by general formula 1 and compound represented by general formula 2. In general formula 1, R.sup.1 to R.sup.8, and B.sup.1 and B.sup.2 each represent hydrogen atom or substituent, and at least either of B.sup.1 and B.sup.2 represents monovalent group represented by general formula 3; in general formula 2, R.sup.9 to R.sup.16, and B.sup.3 and B.sup.4 each represent hydrogen atom or substituent, and at least either of B.sup.3 and B.sup.4 represents monovalent group represented by general formula 3; and in general formula 3, Ar.sup.1 represents aryl group or heteroaryl group, R.sup.18 represents hydrogen atom or substituent, Ar.sup.1 and R.sup.18 may be coupled to form ring structure via single bond or divalent linking group, and * represents bonding position to adjacent carbon atom.

##STR00001##

An optical article including one or more photochromic compounds selected from group consisting of compound represented by general formula 1 and compound represented by general formula 2. In general formula 1, R.sup.1 to R.sup.8, and B.sup.1 and B.sup.2 each represent hydrogen atom or substituent, and at least either of B.sup.1 and B.sup.2 represents monovalent group represented by general formula 3; in general formula 2, R.sup.9 to R.sup.16, and B.sup.3 and B.sup.4 each represent hydrogen atom or substituent, and at least either of B.sup.3 and B.sup.4 represents monovalent group represented by general formula 3; and in general formula 3, Ar.sup.1 represents aryl group or heteroaryl group, R.sup.18 represents hydrogen atom or substituent, Ar.sup.1 and R.sup.18 may be coupled to form ring structure via single bond or divalent linking group, and * represents bonding position to adjacent carbon atom.

##STR00001##